Paul Lorigan is a Professor of Medical Oncology at the University of Manchester and Honorary Consultant Medical Oncologist at the Christie NHS Foundation Trust. He leads a research based clinical medicine, specialising in developing new treatments for malignant melanoma. He is Chair Elect of Melanoma Focus (www.melanomafocus.org), the UK national charity dedicated to research, treatment, education and information for clinical teams treating melanoma patients, for patients and their families. Previously he chaired the UK NCRI Melanoma Clinical Studies Group from 2006 to 2012 transforming it from failing to successful, and is a member of the EORTC Melanoma Group and a number of other research groups. He is principal investigator on a number of international clinical trials. The Manchester group are international leaders in research and treatment of melanoma, with expertise in signalling pathways (Professor Richard Marais) circulating tumour cells (Professor Caroline Dive), immunotherapy and adoptive cell therapy (Professor Robert Hawkins), and pre-clinical melanoma models (Dr Claudia Wellbrock, Dr Adam Hurlstone). Manchester is the only centre in the UK able to deliver Adoptive Cell Therapy for melanoma, and only one of three in Europe. Paul Lorigan leads the clinical team that works closely with these groups, developing a model of pesonalised medicine in melanoma. This also allows a link between research in targeted therapy and immunotherapy, and greatly strengthens the centre's research output and competitive ability with the other five to six main centres leading internationally in this area. Paul Lorigan has been involved in a number of other projects. He was expert advisor to NICE in the Single Technology Appraisals (STA) of both ipilimumab and vemurafenib, is an advisor to Factor 50, and is a member of the Melanoma Forum. He also acts in the advisory capacity to many national and international groups. He is principal investigator on a number of international studies in this area and has been a co-author on many of the definitive studies in the last 10 years. Professor Lorigan has published over 100 peer reviewed papers.
Rare Cancers Research Group
International Collaborative Group
European Society of Medical Oncology
Society for Melanoma Research
EORTC Melanoma Group
EORTC Melanoma Group Advanced Disease Subgroup
EORTC Lung Group
American Society for Clinical Oncology
European Journal of Cancer Editorial Board
International Association for Study of Lung Cancer
Christie Hospital Melanoma Disease Orientated Group: Chair 2002 – present
Melanoma Task Force: (Parliamentary Group)
Royal College of Physicians Appointment Committee
Melanoma Focus (Charity): Chair Elect
Melanoma Research Fund (Charity) Trustee
Challenge for Life (Charity) Trustee
Paul Lorigan leads a research based clinical medicine, specialising in developing new treatments for malignant melanoma.
Melanoma Research has been prioritised by MCRC as one of the six tumour types for development with the aim of making these internationally competitive. Paul Lorigan (PL) is progressing this:
Leading research at an international level as a major contributor (currently UK PI for two ongoing studies) and author on nearly all of the most important international studies in small cell lung cancer in the last five years and continuing to lead for the Lung group in this area.
MB, BCH, BAO, BA, FRCP
Paul Lorigan (PL) has extensive experience as Principal Investigator in Phase I/II and III trials for nearly 20 years in Malignant Melanoma and lung cancer.
PL leads research at an international level and is a major contributor to pivotal clinical trials evaluating new treatment approaches that have revolutionized management of advanced melanoma. Key involvement in drawing up UK guidelines for use of these new treatments and expert advisor to NICE for review of these agents 2012.
PL is key to delivering melanoma research, an MCRC priority
Selected Teaching Lectures